ACOG Alpha Cognition Inc.
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development pro…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Alpha Cognition (ACOG) Stock Fair Value Rises After Zunveyl Analyst Optimism The fair value price target for Alpha Cognition has shifted from about US$14.67 to US$16.75, which places the stock in a higher valuation range than before. Recent analyst commentary links this move to expectations around Zunveyl, including early launch progress, payer access, and the potential to address tolerability issues seen with existing Alzheimer’s therapies. As you read on, you will see how these factors fit into the evolving Alpha Cognition story and how to track new information as... | ||
 Alpha Cognition Inc. Common Stock Q2 2026 Earnings Call Summary Moby summary of Alpha Cognition Inc. Common Stock's Q2 2026 earnings call | ||
 Alpha Cognition (ACOG) Q2 2026 Earnings Call Transcript ZUNVEYL revenue surged 71% sequentially as repeat prescriber rates hit 76%. | ||
 Alpha Cognition Q2 Earnings Call Highlights Alpha Cognition (NASDAQ:ACOG) reported second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer’s treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the first quarter, as the company cited growing prescriber adoption and deeper use in long-term care facil | ||
 Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of -2.56% and +41.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Liquidia Corporation (LQDA) Q2 Earnings and Revenues Beat Estimates Liquidia Corporation (LQDA) delivered earnings and revenue surprises of +5.71% and +3.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.28% and +17.44%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Alpha Cognition Inc. (ACOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | ||
 Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +9.14% and +97.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Alpha Cognition Inc. (ACOG) Surges 8.6%: Is This an Indication of Further Gains? Alpha Cognition Inc. (ACOG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. | ||